Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Viswanatha

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Haematologica|May 18, 2023
Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasmsTalha Badar, Ahmad Nanaa, James M Foran, et al.
Leukemia & Lymphoma|November 6, 2024
Clinical outcomes of patients diagnosed with <i>SETBP1</i> mutated myeloid neoplasmsYazan Jabban, Mahmoud Yacout, Anmol Baranwal, et al.
Blood Advances|December 8, 2022
Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experienceBahga Katamesh, Ahmad Nanaa, Rong He, et al.
Haematologica|September 8, 2022
Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survivalAyalew Tefferi, Amritpal Singh, Naseema Gangat, et al.
American Journal of Hematology|September 20, 2018
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational statusKebede H Begna, Walid Ali, Naseema Gangat, et al.
Hematological Oncology|October 23, 2025
Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid NeoplasmsMuhamad Oum, Ahmad Nanaa, Yazan Jabban, et al.
Blood Cancer Journal|February 10, 2021
Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosisBeth A Pitel, Neeraj Sharma, Cinthya Zepeda-Mendoza, et al.
Blood Cancer Journal|March 3, 2021
Mayo Clinic experience with 1123 adults with acute myeloid leukemiaKebede H Begna, Walid Ali, Naseema Gangat, et al.
Leukemia Research|October 10, 2025
Applicability of current prognostication models for MDS patients with DDX41 mutationNadia Toumeh, Yazan Jabban, Rong He, et al.
Annals of Hematology|August 28, 2024
Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experienceBahga Katamesh, Ahmad Nanaa, Rong He, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Haematologica|May 18, 2023
Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasmsTalha Badar, Ahmad Nanaa, James M Foran, et al.
Leukemia & Lymphoma|November 6, 2024
Clinical outcomes of patients diagnosed with <i>SETBP1</i> mutated myeloid neoplasmsYazan Jabban, Mahmoud Yacout, Anmol Baranwal, et al.
Blood Advances|December 8, 2022
Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experienceBahga Katamesh, Ahmad Nanaa, Rong He, et al.
Haematologica|September 8, 2022
Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survivalAyalew Tefferi, Amritpal Singh, Naseema Gangat, et al.
American Journal of Hematology|September 20, 2018
A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational statusKebede H Begna, Walid Ali, Naseema Gangat, et al.
Hematological Oncology|October 23, 2025
Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid NeoplasmsMuhamad Oum, Ahmad Nanaa, Yazan Jabban, et al.
Blood Cancer Journal|February 10, 2021
Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosisBeth A Pitel, Neeraj Sharma, Cinthya Zepeda-Mendoza, et al.
Blood Cancer Journal|March 3, 2021
Mayo Clinic experience with 1123 adults with acute myeloid leukemiaKebede H Begna, Walid Ali, Naseema Gangat, et al.
Leukemia Research|October 10, 2025
Applicability of current prognostication models for MDS patients with DDX41 mutationNadia Toumeh, Yazan Jabban, Rong He, et al.
Annals of Hematology|August 28, 2024
Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experienceBahga Katamesh, Ahmad Nanaa, Rong He, et al.
Pageof 6